Shots:
- Vividion to receive $1.5B up front & $500M milestone while Bayer to get full rights to Vividion’s discovery platform which consists of chemoproteomic screening technology, a data portal, and a chemistry library. The transaction is expected to close in Q3’21
- The acquisition will strengthen Bayer’s drug discovery capabilities & expand it into new modalities. The acquisition will also increase the value of Vividion’s pipeline
- Vividion’s technology has the potential to expand into additional indications as it is already proved in oncology & immune-related diseases in preclinical studies
Click here to read full press release/ article | Ref: Bayer | Image: The Business Journals
The post Bayer to Acquire Vividion for ~$2B first appeared on PharmaShots.
